Amplifold Raises EUR 5 Million Seed for Diagnostics

Munich-based Amplifold closed an oversubscribed EUR 5 million Seed round. Matterwave Ventures and XISTA Science Ventures co-led the deal. Bayern Kapital, b2venture, and Becker Ventures joined in.

Funding details: EUR 5 million (Seed)

Full Story

Amplifold raised EUR 5 million in an oversubscribed Seed round.

The round was co-led by Matterwave Ventures and XISTA Science Ventures. Bayern Kapital, b2venture, and Becker Ventures (part of Labor Becker Group) also invested.

The funds will help industrialise the DNA-origami signal amplification platform for lateral flow assays. They will support product development and regulatory work to get the first in vitro diagnostic product approved under IVDR in Europe.

Dr Enzo Kopperger, co-founder and managing director, said the tech can give about 100 times better sensitivity without much extra cost. It fits into existing manufacturing lines so partners can improve their tests quickly without starting over.

Dr Maximilian Urban, co-founder and managing director, said lateral flow tests made diagnostics more accessible but were not as sensitive as lab equipment. The DNA-origami boost lets cheap rapid tests get close to that lab-level accuracy while keeping the same simple format.

Amplifold builds rapid diagnostic tests using DNA-origami nanotechnology. The platform boosts sensitivity in standard lateral flow assays for better detection. The company is a spin-off from Ludwig-Maximilians-Universität München and operates in Germany.

Source:- EU-Startups.